Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 39Ovarian Neoplasms 29Multiple Myeloma 16Neoplasms 9Recurrence 8Lymphoma 8Fallopian Tube Neoplasms 8Triple Negative Breast Neoplasms 7Lymphoma, Large B-Cell, Diffuse 7Hodgkin Disease 7Carcinoma, Ovarian Epithelial 7Lymphoma, Non-Hodgkin 6Sarcoma 5Neoplasm Metastasis 5Burkitt Lymphoma 3Uterine Cervical Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Mesothelioma, Malignant 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lung Neoplasms 2Liver Neoplasms 2Leukemia 2Leiomyosarcoma 2Kidney Neoplasms 2Endometrial Neoplasms 2Disease Progression 2Vulvar Neoplasms 1Vaginal Neoplasms 1

Interventions

Paclitaxel 6Taxes 5Carboplatin 5Immunoglobulin G 2Disulfides 2Bevacizumab 2sargramostim 1liposomal doxorubicin 1emactuzumab 1elesclomol 1belinostat 1adavosertib 1VTX-2337 1Surgical Procedures, Operative 1Metformin 1Immunologic Techniques 1Imatinib Mesylate 1Granulocyte-Macrophage Colony-Stimulating Factor 1Gemcitabine 1Erlotinib Hydrochloride 1Drug Therapy 1Cytoreduction Surgical Procedures 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Brenner Tumor × liposomal doxorubicin × Clear all
NCT01666444 2019-09-26

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Celgene

Phase 2 Completed
297 enrolled 15 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Brenner Tumor, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡